AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort. The study reported a median duration of response of 8.7 months and a ...
NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations. Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus ...
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...
Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and ...
CAMBRIDGE, Mass. and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families ...
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results